1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow Endocarditis, Bacterial: new trials by email Literature Review of Endocarditis, Bacterial trials Research Report on Endocarditis, Bacterial
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia daptomycin, vancomycin - Endocarditis, Bacterial, Infective Endocarditis | Phase 2 | Terminated | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 38 | 2008-09-17 | 2018-12-24 |
Bacteremia (1) · Endocarditis (1) · Gram-Positive Bacterial Infections (1) · Staphylococcal Infections (1)
Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Cardiovascular Diseases (1) · Cardiovascular Infections (1) · Heart Diseases (1) · Infections (1) · Inflammation (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Sepsis (1) · Systemic Inflammatory Response Syndrome (1)
Daptomycin (1) · Injections (1) · Vancomycin (1)
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)
United States (1)
Peter Pertel, MD (1)